INL and UMinho Collaborate with IPLEXMED to Revolutionize Graphene-Based Diagnostics
In a groundbreaking development, the International Iberian Nanotechnology Laboratory (INL) and the University of Minho (UMinho) have recently partnered with IPLEXMED, a forward-thinking medical diagnostics company, to bring a cutting-edge graphene-based diagnostic platform to market. This collaboration marks a significant step forward in the field of advanced materials and medical technology.
The technology in question, developed under the MULTIMAL project and patented in 2024 with the support of the prestigious HORIZON 2020 program, utilizes monolayer graphene field-effect transistor (FET) sensors. These sensors are engineered to detect malaria and other diseases with remarkable precision, offering non-invasive, rapid, and highly sensitive results from saliva or urine samples. The performance is so advanced that it can detect diseases at the attomolar level, a feat that was once thought to be impossible.
According to INL leadership, this agreement signifies a pivotal moment in the transition of graphene sensor technology from the research laboratory to the commercial marketplace. It demonstrates the tangible, real-world applications of advanced materials, showcasing how scientific breakthroughs can translate into practical solutions that benefit society.
This collaboration between INL, UMinho, and IPLEXMED highlights the power of interdisciplinary research and the potential for innovation in the healthcare sector. By combining cutting-edge technology with practical applications, this partnership is poised to make a significant impact on the future of medical diagnostics.
